Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Bosch, J; Lonn, EM; Jung, H; Zhu, J; Liu, LS; Lopez-Jaramillo, P; Pais, P; Xavier, D; Diaz, R; Dagenais, G; Dans, A; Avezum, A; Piegas, LS; Parkhomenko, A; Keltai, K; Keltai, M; Sliwa, K; Held, C; Peters, RJG; Lewis, BS; Jansky, P; Yusoff, K; Khunti, K; Toff, WD; Reid, CM; Varigos, J; Joseph, P; Leiter, LA; Yusuf, S

Bosch, J (corresponding author), Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada.; Bosch, J (corresponding author), McMaster Univ, Sch Rehabil Sci, IAHS, Room 403,1400 Main St West, Hamilton, ON L8S 1C7, Canada.

EUROPEAN HEART JOURNAL, 2021; 42 (31): 2995

Abstract

Aims Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) events by 24% in 12 705 participants at intermediate......

Full Text Link